Inhaled Iloprost for Sarcoidosis-associated Pulmonary Hypertension

Inclusion Criteria: * Patients with known sarcoidosis 17 * Age 18 or greater * Patients with documented pulmonary hypertension with a PA mean \> 25 mm as measured by cardiac catheterization within six months of entry into the study * Patients with dyspnea * Six minute walk distance of between 100 to 500 meters * Patients on stable immunotherapy for their sarcoidosis, including prednisone, methotrexate, azathioprine, hydroxychloroquine, cyclophosphamide, thalidomide, and/or infliximab * Patients able to provide written consent Exclusion Criteria: * Patients on pulmonary vasodilator drugs (flolan, remodulin, bosentan, sildenafil) in the prior 28 days (patients on stable dose of calcium channel blocker for more than 1 month prior to right heart catheterization can be continued on the calcium channel blocker) * Patients with severe airway obstruction as defined by FEV1/FVC of less than 35% * Patients with World Health Organization (WHO) class IV status * Patients who are pregnant or breast feeding * Patients with significant left ventricular dysfunction with a left ventricular ejection fraction of less than 35% * Significant liver dysfunction not due to sarcoidosis * Patients with severe other organ disease felt by investigators to impact survival during the course of the study * Patients unable to perform the 6 inhalation treatments required for therapy * Patients with \< 90 mm Hg Systolic systemic blood pressure will be excluded